- Previous Close
0.630 - Open
0.630 - Bid 0.630 x --
- Ask 0.640 x --
- Day's Range
0.620 - 0.640 - 52 Week Range
0.495 - 1.020 - Volume
16,674,000 - Avg. Volume
25,167,101 - Market Cap (intraday)
5.843B - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-0.020 - Earnings Date Mar 28, 2025
- Forward Dividend & Yield 0.02 (3.33%)
- Ex-Dividend Date Sep 27, 2024
- 1y Target Est
--
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China. The company operates through three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. It offers filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care, and others, as well as non- or minimally invasive medical aesthetics comprehensive solutions. It offers drugs in the oncology, metabolism, diabetes, cardiovascular and cerebrovascular, modern Chinese medicine, and industrial hemp therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing. In addition, it provides information support, general hospital, hospital management, and biotechnology and technology promotion services. Sihuan Pharmaceutical Holdings Group Ltd. was founded in 2001 and is based in Wan Chai, Hong Kong.
www.sihuanpharm.com2,667
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 0460.HK
View MorePerformance Overview: 0460.HK
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0460.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0460.HK
View MoreValuation Measures
Market Cap
5.84B
Enterprise Value
2.78B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.89
Price/Book (mrq)
1.26
Enterprise Value/Revenue
1.37
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-11.40%
Return on Assets (ttm)
-2.21%
Return on Equity (ttm)
-9.35%
Revenue (ttm)
1.9B
Net Income Avi to Common (ttm)
-216.66M
Diluted EPS (ttm)
-0.020
Balance Sheet and Cash Flow
Total Cash (mrq)
3.63B
Total Debt/Equity (mrq)
19.05%
Levered Free Cash Flow (ttm)
--